Rapid Micro Biosystems, Inc. filings document the company's microbial quality-control automation business, governance matters and capital structure. Form 8-K reports furnish operating results, preliminary revenue updates, Regulation FD disclosures about the Growth Direct platform, and material agreements such as term-loan financing secured by company assets and related warrants for Class A common stock.
Proxy filings cover annual meeting procedures, stockholder voting matters, board governance and executive compensation disclosures. Other material-event reports address officer-transition and compensatory-arrangement disclosures, while recent cover pages identify the company as an emerging growth company for Exchange Act reporting purposes.
RAPID MICRO BIOSYSTEMS, INC. chief operating officer John J. Wilson reported an automatic sale of 5,403 shares of Class A common stock at $3.923 per share. According to the footnote, this sale was made solely to cover tax obligations tied to vesting restricted stock units. After the transaction, he directly held 326,365 shares of Class A common stock.
RAPID MICRO BIOSYSTEMS, INC. Chief Financial Officer Sean M. Wirtjes reported an automatic sale of Class A common stock to cover taxes tied to restricted stock unit vesting. He sold 17,254 shares at an average price of $3.923 per share. After this tax-related sale, he continues to hold 563,674 shares directly.
RAPID MICRO BIOSYSTEMS, INC. president and CEO Robert G. Spignesi Jr. reported a sale of 38,327 shares of Class A common stock on February 19, 2026 at an average price of $3.8853 per share. A footnote explains this was an automatic sale to cover tax obligations arising from the vesting of restricted stock units, rather than a discretionary open-market trade. After this transaction, he still holds 1,187,770 shares of the company’s Class A common stock directly.
RPID reported a proposed sale of 5,403 shares of Class A common stock under Rule 144.
The notice shows the shares are associated with a Restricted Stock Vesting event dated 02/19/2026, and it discloses a prior sale of 4,610 shares on 02/09/2026.
Sean M. Wirtjes reports a proposed sale of Class A shares. The notice lists 17,254 Class A shares to be sold in connection with restricted stock vesting dated 02/19/2026. The filing also reports 6,027 Class A shares sold on 02/09/2026.
RPID filed a Form 144 reporting a proposed sale of Class A shares by an affiliate. The filing lists 38,327 Class A shares to be sold with an aggregate amount of $148,911.89, dated 02/18/2026. The filing also shows 12,840 Class A shares sold during the past three months for $48,569.87.
Rapid Micro Biosystems chief operating officer John J. Addington Wilson received new equity awards as part of his compensation. He was granted 74,000 shares of Class A common stock, reported at a price of $0 and bringing his direct holdings to 331,768 shares. These shares represent restricted stock units that vest over three years, with 33.4% vesting on the first anniversary of February 11, 2026 and 33.3% on each of the next two anniversaries, conditioned on continued service. He was also granted a stock option for 147,000 shares of Class A common stock with a $4.20 exercise price, expiring on February 10, 2036. The option vests in 48 equal monthly installments starting March 11, 2026, leaving him with 147,000 options beneficially owned after the transaction.
Rapid Micro Biosystems, Inc. reported an equity compensation grant to its Chief Financial Officer, Sean M. Wirtjes. On February 11, 2026, he received 97,000 Class A common stock restricted stock units, awarded at $0 per share, increasing his directly held Class A shares to 580,928 after the grant.
He was also granted a stock option for 193,000 shares of Class A common stock with an exercise price of $4.2 per share. The RSUs vest in three annual installments starting on the first anniversary of the grant date, while the option vests in 48 equal monthly installments beginning March 11, 2026, contingent on continued service.
Rapid Micro Biosystems, Inc. President and CEO Robert G. Spignesi Jr., who is also a director, reported equity compensation awards. He received 264,000 shares of Class A common stock on February 11, 2026 as a grant of restricted stock units that vest over three years.
The RSUs vest in three annual installments, with 33.4% vesting on the first anniversary of the February 11, 2026 grant date and 33.3% vesting on each of the next two anniversaries, subject to continued service. He was also granted a stock option covering 528,000 shares at an exercise price of $4.20 per share, vesting in 48 equal monthly installments starting March 11, 2026 and expiring February 10, 2036. Following these awards, he directly beneficially owns 1,226,097 shares of Class A common stock and 528,000 stock options.
Rapid Micro Biosystems, Inc. (RPID) received an updated ownership disclosure showing that investment entities affiliated with Endeavour Medtech collectively report beneficial ownership of 2,257,099 shares of Class A common stock, representing 5.7% of the class, based on 39,823,026 shares outstanding as of October 31, 2025.
The shares are held of record by Endeavour Medtech Growth II LP (2,217,190 shares) and Endeavour Medtech Growth II Parallel LP (39,909 shares), with Endeavour Medtech II GP Limited as general partner. The reporting group certifies the holdings are not for the purpose of changing or influencing control of the company.